Tours

• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended recruitment
  2022-503091-89-00 4 2024-02-15 Delayed graft function
• Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran … Ended recruitment
  2024-514876-41-00 9 2023-12-06 Higher-risk myelodysplastic syndromes untreated and ineligible for all
• Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended recruitment
  2024-514878-53-00 4 2023-10-04 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk intermediate-2 or
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancer Ended recruitment
  2022-501518-67-00 4 2023-08-10 High-risk and/or locally advanced prostate cancer
• Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr … Ended recruitment
  2022-501179-23-00 6 2023-03-08 atopic dermatitis
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended recruitment
  2022-500138-27-01 5 2023-02-28 Multiple Myeloma
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended recruitment
  2023-504832-16-00 4 2023-01-24 DIFFUSE LARGE B CELL LYMPHOMA
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has … Ended recruitment
  2024-514644-93-00 5 2022-12-09 Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti … Ended recruitment
  2023-505866-27-00 5 2022-10-28 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended recruitment
  2023-509229-31-00 5 2022-09-28 Metabolic Disorders - Phenylketonuria
• Avalglucosidase alfa French post-trial access for participants with Pompe disease Ended recruitment
  2024-514773-22-00 6 2022-07-11 Glycogen storage disease type II
• DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel … Ended recruitment
  2024-518244-20-01 4 2022-04-25 Urothelial Carcinoma
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION ( … Ended recruitment
  2024-515037-15-00 4 2022-03-02 PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI
• Multi-drug treatment for breast cancer patients with brain metastases Ended recruitment
  2024-510703-11-00 4 2021-12-13 HER2+ metastatic breast cancer with isolated brain progression
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients … Ended recruitment
  2024-516651-41-00 5 2021-10-08 COPD : chronic obstructive Pulmonary disease
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Showing 217–240 of 314 trials